COVID-19 Support

Announcement

Gemini Bio Announces Its Dedicated Effort to Help Support COVID-19 Research

* Gemini Bio’s Key Products are Supporting the Fight against COVID-19

WEST SACRAMENTO, CA, April 29, 2020 – Gemini Bioproducts, LLC (“Gemini” or “Gemini Bio”), a leading supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, today announced its effort to help support COVID-19 research.

According to the WHO, there are over 200 countries with 2.9 million confirmed cases and over 202,000 confirmed deaths, as of the time of this release.

Post

Precision Tools for your COVID-19 Workflow

To support labs pivoting to COVID-19 research, Gemini Bio is prioritizing products and services to assist its customers in four key areas: (1) cell culture, (2) viral harvesting and transport, (3) research tools, and (4) analytical instruments.

Cell Culture Viral Harvesting/Transport Research Tools Analytical Instruments
Human Serum Viral Transport Media (Bulk or Custom Fill Sizes) Cryostorage Medium Moxi Z Cell Counter
Gamma-Irradiated Fetal Bovine Serum Amphotericin B and Gentamicin Growth Factors Moxi GO II Cell Analyzer
Custom Media Hanks’ Balanced Salt Solution (Bulk or Custom Fill Sizes) Cytokines  
Enzymatic Dissociation Sterile Conical Tubes & Pipettors Albumins  
Bioreactor Solutions